AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8113482
Drug: Sexual assault
RxNorm normalized name: Zinc Gluconate 50 mg ORAL CAPSULE [Pegasus Male Sexual Enhancer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sexual assault prevention program (treatment group)
Trial: 31413088
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg iron as ferrous sulfate on alternate days
Trial: 31413088
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg iron as ferrous sulfate on consecutive days
Trial: 31413088
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg iron as ferrous sulfate on consecutive days
Trial: 31413088
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg iron as ferrous sulfate on alternate days vs 200 mg on consecutive days
Trial: 29669086
Drug: PA +
RxNorm normalized name: PAS
DrugBank: Aminosalicylic acid (DB00233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PA + CBT‐P group (physical activity plus cognitive-behavioral therapy for pain)
Trial: 10661483
Drug: Augmented blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Augmented blood flow and saline flush (200‐250 ml/min and 100 ml twice hourly)
Trial: 3531308
Drug: Ranitidine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine treatment in second 4-week period for 124 unhealed patients
Trial: 19248105
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid (HA) injection (2.5 ml)
Trial: 19248105
Drug: Placebo injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injection (2.5 ml)
Trial: 11723147
Drug: Normal-carbohydrate meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal-carbohydrate meal (65 g)
Trial: 11723147
Drug: High-carbohydrate meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-carbohydrate meal (125 g)
Trial: 9340918
Drug: Beta-blockers and
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blockers and platelet aggregation inhibitors
Trial: 3565242
Drug: Computer-aided dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer-aided dosing (Bayesian forecasting technique)
Trial: 3565242
Drug: Control (unaided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (unaided physician dosing)
Trial: 3565242
Drug: Lidocaine concentrations
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine concentrations greater than 2 mg/L
Trial: 31852769
Drug: 30 g
RxNorm normalized name: Lancet Unilet 30 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g FMT
Trial: 31852769
Drug: 60 g
RxNorm normalized name: aspirin 60 Grains
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 g FMT
Trial: 22718671
Drug: Extract of
RxNorm normalized name: Extract of tomato
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extract of Valeriana Officinalis L. (765 mg/day)
Trial: 22718671
Drug: Placebo (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (30 mg/day)
Trial: 19384840
Drug: Olmesartan (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan (initial dose 5 mg, increased to 10 mg, 20 mg, and 40 mg over 16 weeks)
Trial: 14623807
Drug: Water ingestion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water ingestion (16 oz / 473 mL) 5 minutes before tilt-table testing
Trial: 8783054
Drug: No washing
RxNorm normalized name: Zencia Wash
DrugBank: Octasulfur (DB09353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No washing (control group), 30s washing 2X daily for 7 days
Trial: 22325733
Drug: Gabapentin enacarbil
RxNorm normalized name: Gabapentin Enacarbil
DrugBank: Gabapentin enacarbil (DB08872)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin enacarbil 1200 mg
Trial: 8698375
Drug: Topical clotrimazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical clotrimazole applied twice daily for 7 days
Trial: 1519716
Drug: Ibuprofen/codeine combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen/codeine combination (400 mg ibuprofen/25.6 mg codeine phosphate)
Trial: 1519716
Drug: Paracetamol/codeine/caffeine combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol/codeine/caffeine combination (1 g paracetamol/16 mg codeine phosphate/60 mg caffeine)
Trial: 6503363
Drug: 360 J
RxNorm normalized name: Vitamin J
DrugBank: Choline (DB00122)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 360 J (maximal energy dose available in most defibrillators)
Trial: 19053970
Drug: Open sequential
RxNorm normalized name: BOTTLE OPENER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open sequential treatment protocol (augmentation with lithium, switch to a monoamine oxidase inhibitor or ECT)
Trial: 19053970
Drug: Augmentation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Augmentation with lithium
Trial: 8362305
Drug: Halofantrine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Halofantrine (3 doses of 500 mg at 6 hour intervals)
Trial: 8362305
Drug: Mefloquine (divided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mefloquine (divided doses of 1,250 mg or 1,500 mg based on weight)
Trial: 21567070
Drug: sivelestat (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sivelestat (0.2 mg/kg/h from induction of anesthesia to post-operative day 1)
Trial: 15328756
Drug: BN165 (Ginkor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BN165 (Ginkor Fort) 3 capsules per day
Trial: 11002713
Drug: Epidural infusion
RxNorm normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural infusion of alfentanil at T5-7 (group T)
Trial: 9149197
Drug: Tensilon 10
RxNorm normalized name: Tensilon 10 MG/ML Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tensilon 10 mg i.v.
Trial: 3766854
Drug: Amoscanate 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoscanate 1 mg/kg
Trial: 6134827
Drug: Weekly sessions
RxNorm normalized name: Alternanthera sessilis extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly sessions
Trial: 30354784
Drug: Drug-eluting stents
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-eluting stents (Zilver PTX stent implantation without cilostazol)
Trial: 25566620
Drug: Yindan Xinnaotong
RxNorm normalized name: Lindane
DrugBank: Lindane (DB00431)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Yindan Xinnaotong Soft Capsule (YXSC)
Trial: 30650286
Drug: Naoxintong Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naoxintong Capsule (NC)
Trial: 18215592
Drug: Glycoprotein IIb/IIIa
RxNorm normalized name: GLYCOPROTEIN IIB/IIIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycoprotein IIb/IIIa inhibitors or clopidogrel
Trial: 9124201
Drug: TAE plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAE plus 5'-DFUR (400 mg/day)
Trial: 8087578
Drug: Mechanical ventilation
RxNorm normalized name: PIPERONYL BUTOXIDE TECHNICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechanical ventilation treatment modalities
Trial: 8087578
Drug: Treatment protocols
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment protocols
Trial: 21539702
Drug: Transforaminal injection
RxNorm normalized name: transforming growth factor beta 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transforaminal injection of steroids (TFIS)
Trial: 17038949
Drug: COX‐2 inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COX‐2 inhibitor in addition to narcotics (Experimental)
Trial: 1804649
Drug: SR 33557
RxNorm normalized name: SR 121463
DrugBank: SR 121463 (DB05455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SR 33557 (100 mg)
Trial: 29202563
Drug: Nebulized hyaluronic
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized hyaluronic acid (HA) via Spray-sol, twice a day for 10 days (T1)
Trial: 29202563
Drug: Physiological saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiological saline nebulized via Spray-sol, twice a day for 10 days (T2)
Trial: 19668121
Drug: quetiapine XR
RxNorm normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: quetiapine XR 50 mg/day
Trial: 18779774
Drug: quetiapine XR
RxNorm normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: quetiapine XR 300 mg/day
Trial: 17602036
Drug: Milrinone (bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milrinone (bolus and infusion before cardiopulmonary bypass until skin closure)
Trial: 9542478
Drug: Zolmitriptan (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolmitriptan (all doses)
Trial: 8566267
Drug: Pulsatile administration
RxNorm normalized name: PULSATILLA PRATENSIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsatile administration of hMG
Trial: 26413500
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg DHA supplementation
Trial: 25168665
Drug: Duloxetine 60
RxNorm normalized name: duloxetine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 60 mg/d + Pregabalin 300 mg/d
Trial: 25168665
Drug: Combination/high-dose therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination/high-dose therapy
Trial: 23732189
Drug: High-dose monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose monotherapy
Trial: 9726387
Drug: OAM (omeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OAM (omeprazole 20 mg b.d., amoxycillin 1 g b.d., metronidazole 400 mg b.d.)
Trial: 10651664
Drug: OMC (omeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OMC (omeprazole 20 mg b.d., metronidazole 400 mg b.d., clarithromycin 500 mg b.d.)
Trial: 10651664
Drug: Pre-treatment metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pre-treatment metronidazole resistance
Trial: 331920
Drug: Betahistine 24
RxNorm normalized name: betahistine 24 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betahistine 24 mg daily
Trial: 31944221
Drug: Dasatinib (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dasatinib (80 mg/m2 daily)
Trial: 31944221
Drug: Imatinib (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib (300 mg/m2 daily)
Trial: 25321162
Drug: 2.5% mannitol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5% mannitol + 10 mg scopolamine butylbromide
Trial: 25321162
Drug: 2.5% mannitol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5% mannitol + 20 mg scopolamine butylbromide
Trial: 22057498
Drug: HPPH-PDT with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPPH-PDT with 3 mg/m2 HPPH (light dose of 150 J/cm at 48 hours)
Trial: 22057498
Drug: HPPH-PDT with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPPH-PDT with 4 mg/m2 HPPH (light dose at 24 hours)
Trial: 18958483
Drug: Amniotomy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amniotomy and immediate oxytocin infusion
Trial: 18958483
Drug: Amniotomy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amniotomy and delayed oxytocin infusion
Trial: 16775166
Drug: History of
RxNorm normalized name: BEMOTRIZINOL 0.8 mL in 100 mL / OCTINOXATE 7 mL in 100 mL TOPICAL CREAM [THE HISTORY OF WHOO GONG JIN HYANG HAE YOON SUN]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: History of injecting drug use
Trial: 1101820
Drug: Topical polyinosinic
RxNorm normalized name: polyinosinic-polycytidilic acid (Poly-ICLC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical polyinosinic acid-polycytidylic acid [poly(I:C)]
Trial: 15198873
Drug: Transdermal nitroglycerin
RxNorm normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal nitroglycerin at a target dose of 14 microg/kg/h
Trial: 18494791
Drug: 200 mg/day
RxNorm normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/day TPM
Trial: 16813180
Drug: Consciousness‐restoring resuscitation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consciousness‐restoring resuscitation acupuncture (treatment group)
Trial: 16813180
Drug: Chinese medicine
RxNorm normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese medicine (control group)
Trial: 12673081
Drug: KC 2%
RxNorm normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: KC 2% foaming gel
Trial: 12673081
Drug: CIC 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CIC 1% cream
Trial: 1599264
Drug: 17 mg/mL
RxNorm normalized name: menthol 17 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17 mg/mL cyclosporine
Trial: 1599264
Drug: 10 mg/mL
RxNorm normalized name: urea 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/mL cyclosporine
Trial: 1599264
Drug: 2.5 mg/mL
RxNorm normalized name: iodine 2.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg/mL cyclosporine
Trial: 6202408
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of bleomycin
Trial: 6202408
Drug: Intermittent bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent bolus injection of bleomycin
Trial: 30717805
Drug: Liberal transfusion
RxNorm normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liberal transfusion strategy (transfusion of a single RBC unit when Hb ≤ 9 g/dl with a target range for post-transfusion Hb level of 9-10.5 g/dl)
Trial: 25265986
Drug: 3% Rumex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% Rumex occidentalis cream
Trial: 25265986
Drug: 4% Hydroquinone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% Hydroquinone cream
Trial: 20380479
Drug: Ketoprofen syrup
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketoprofen syrup 0.5 mg/kg
Trial: 20380479
Drug: Ibuprofen suspension
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen suspension 5 mg/kg
Trial: 16115978
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate (Mg) 2.48 mmol
Trial: 24910102
Drug: Ketamine 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 0.2 mg/kg
Trial: 12353197
Drug: Valacyclovir 250
RxNorm normalized name: valacyclovir 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valacyclovir 250 mg (9.4‐13.3 mg/kg) twice daily
Trial: 12353197
Drug: Valacyclovir 500
RxNorm normalized name: valacyclovir 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valacyclovir 500 mg (13.2‐21.7 mg/kg) 3 times a day
Trial: 31800752
Drug: Surgical Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical Therapy (ST)
Trial: 31800752
Drug: Nonsurgical Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsurgical Therapy (NST)
Trial: 17623467
Drug: BMS-378806 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS-378806 (100 to 1600 mg single oral dose)
Trial: 17623467
Drug: BMS-378806 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS-378806 (100 to 1200 mg)
Trial: 17623467
Drug: BMS-378806 (1600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS-378806 (1600 mg)
Trial: 15530201
Drug: Daily typed
RxNorm normalized name: turpentine / white spirit type 1 Topical Solution [Cornucrescine Daily Hoof Barrier]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily typed journal group
Trial: 10599182
Drug: Nadolol (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadolol (80 mg)
Trial: 29252047
Drug: Beetroot juice
RxNorm normalized name: tamarind juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beetroot juice (BR; 140 ml/day, ∼800 mg/day nitrate)
Trial: 23413606
Drug: Novel radioisotope
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Novel radioisotope therapies
Trial: 31680143
Drug: Cytotoxic agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytotoxic agents
Trial: 21353117
Drug: New generic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New generic formulation of bicalutamide 50-mg tablets (test)
Trial: 21353117
Drug: Currently marketed
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Currently marketed formulation of bicalutamide 50-mg tablets (reference)
Trial: 17309908
Drug: Gentamicin 2
RxNorm normalized name: gentamicin 2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin 2 mg/kg, rifampicin 600 mg, vancomycin 15 mg/kg (with three further doses of 7.5 mg/kg at 12-hour intervals)
Trial: 17309908
Drug: Cefuroxime 1.5
RxNorm normalized name: cefuroxime 1.5 GM Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefuroxime 1.5 g at induction and three further doses of 750 mg at 8-hour intervals
Trial: 12925049
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of ANP (0.25 microg/kg/min in 0.9% NaCl) after 3 weeks' pre‐treatment with placebo
Trial: 10840536
Drug: Tropisetron 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tropisetron 0.1 mg/kg body weight
Trial: 24489014
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg ORM-12741
Trial: 24489014
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg ORM-12741
Trial: 22828645
Drug: Hib-MenC-TT booster
RxNorm normalized name: TT 173
DrugBank: TT 173 (DB17717)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hib-MenC-TT booster dose
Trial: 9888118
Drug: Weekly contingent
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly contingent condition (three negative test results required for the first take-home privilege)
Trial: 8665128
Drug: Zamifenacin 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zamifenacin 30 mg
Trial: 6099050
Drug: 5-fluorouracil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-fluorouracil at 200 mg/day combined with gestagen at 50 mg/day
Trial: 6099050
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose estrogen (hexestrol at 60 mg/day)
Trial: 6099050
Drug: 5-fluorouracil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-fluorouracil at 200 mg/day combined with hexestrol at 30 mg/day
Trial: 6099050
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose estrogen (hexestrol at 60 mg/day) in patients already well controlled
Trial: 27339107
Drug: 16% carbohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16% carbohydrate solution (CHO)
Trial: 22929967
Drug: Microneedle treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microneedle treatment + daily topical application of diclofenac sodium
Trial: 11814510
Drug: Surgical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical therapy for prolapse
Trial: 31070463
Drug: Ropivacaine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine with clonidine 2 μg/kg
Trial: 31070463
Drug: Ropivacaine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine and a subcutaneous injection of clonidine 2 μg/kg (SC clonidine)
Trial: 28403589
Drug: Palmitoylethanolamide 300
RxNorm normalized name: Palmitoylethanolamide
DrugBank: Palmidrol (DB14043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palmitoylethanolamide 300 mg plus Alpha‐lipoic acid 300 mg (Peanase®)
Trial: 28403589
Drug: Serenoa Repens
RxNorm normalized name: Serenoa Repens Fruit
DrugBank: Saw palmetto (DB14360)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serenoa Repens at 320 mg
Trial: 25456116
Drug: Dexmedetomidine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine infusion (0.5 μg · kg(‐1) initial dose followed by 0.4 μg · kg(‐1) h(‐1))
Trial: 25456116
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline infusion (NS group)
Trial: 30638863
Drug: VIS410 4000
RxNorm normalized name: IMMUNOGLOBULIN G1, ANTI-(INFLUENZA HEMAGGLUTININ) (HUMAN MONOCLONAL VIS410 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN MONOCLONAL VIS410 .KAPPA.-CHAIN, DIMER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VIS410 4000 mg
Trial: 30638863
Drug: VIS410 2000
RxNorm normalized name: IMMUNOGLOBULIN G1, ANTI-(INFLUENZA HEMAGGLUTININ) (HUMAN MONOCLONAL VIS410 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN MONOCLONAL VIS410 .KAPPA.-CHAIN, DIMER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VIS410 2000 mg
Trial: 30073693
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose cyclosporine A